EP Global Communications, Inc., Announces First Orders for MPDD Medical Device 
 
and the Addition of Eric Lee M.D. M.A. to Medical Team 
 
 
 
IRVINE, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- via PRWEB - EP Global 
 
Communications, Inc. (the Company), (Pink Sheets:EPGL.PK), is pleased to 
 
announce that it is receiving first orders for the FDA 510k cleared MPDD 
 
medical device, in advance of the worldwide release of the device in 2013. The 
 
Company is also pleased to announce that Eric Lee, M.D. M.A. has joined the 
 
Company and will oversee further additions to the medical management team and 
 
advancement of new medical devices technologies the Company has interest in 
 
pursuing. 
 
 
 
Eric Lee M.D. M.A. graduated from Yale University and completed medical school 
 
at Boston University. He completed his residency in Physical Medicine and 
 
Rehabilitation at NYU Langone Medical Center where he has continued with a 
 
Pain Medicine fellowship. Dr. Lee is intimately familiar with the MPDD device 
 
and used it as a diagnostic tool in a study of using advanced techniques to 
 
treat myofascial pain along with Dr. Michel Dubois MD at NYU. Dr. Lee's 
 
professional interests include pain diagnosis and treatment, disorders of the 
 
spine, central, and peripheral nervous system, with a special interest in 
 
advanced interventional techniques and minimally invasive spinal procedures. 
 
"The MPDD has the potential to become a universal and consistently reliable 
 
device for numerous physicians to diagnose certain pain syndromes and 
 
therefore lead to more efficient and optimum treatments for patients." says 
 
Dr. Lee. EPGL has set the first quarter of 2013 as its planned release 
 
time-frame for the MPDD device worldwide. 
 
 
 
First advance orders for new MPDD devices are now being received from 
 
physicians and the Company is anticipating very strong demand in 2013 after 
 
worldwide distribution release. The MPDD devices will initially be marketed 
 
under the therapeutic label and later will be marketed under the diagnostic 
 
label with an additional FDA 510k. MPDD devices will be priced between 
 
$12,000.00 and $20,000.00 depending on the package level of training and 
 
education purchased by physicians and health organizations. The Company will 
 
market to pain physicians, primary physicians, Internists, sports medicine 
 
physicians and physical therapists to name just a few in the significant 
 
market for the MPDD device. The MPDD device is only the first of several 
 
products which the Company will market in the months and years ahead as the 
 
Company is extremely interested in the promising field of bioelectronics and 
 
non-opioid treatments of pain. 
 
 
 
Shareholders are the most important asset to EPGL Med. The Company is 
 
committed to growing significant market capitalization and shareholder 
 
returns. To this end, the Company is now taking requisite steps to resume full 
 
reporting status and move up to OTCBB in the near future. New financial 
 
statements and filings will begin by end of year 2012. 
 
 
 
Shareholders can expect additional announcements shortly about additional 
 
management personnel, new offices and new name. Please follow us on Twitter 
 
@EPGLMed and the new website under construction is http://www.epglmed.com. 
 
 
 
About EP Global Communications, Inc. 
 
 
 
EP Global Communications, Inc. is a medical device manufacturer and marketing 
 
company with exclusive rights to a new FDA 510k cleared medical device called 
 
the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic 
 
tool for the detection of muscular originated pain in the human body.